|
Re: BETonMACE Enrollment
|
3
|
Resverlogix Corp.
|
Aug 30, 2017 07:30PM
|
|
Re: Warrants
|
3
|
Resverlogix Corp.
|
Aug 29, 2017 11:56PM
|
|
Re: Warrants
|
3
|
Resverlogix Corp.
|
Aug 29, 2017 11:46AM
|
|
Re: Symposium at ESC in Barcelona
|
2
|
Resverlogix Corp.
|
Aug 26, 2017 07:35PM
|
|
Re: Symposium at ESC in Barcelona
|
2
|
Resverlogix Corp.
|
Aug 26, 2017 07:29PM
|
|
Re: Symposium at ESC in Barcelona
|
2
|
Resverlogix Corp.
|
Aug 26, 2017 07:26PM
|
|
Re: Courtesy
|
5
|
Resverlogix Corp.
|
Aug 23, 2017 10:47AM
|
|
Re: 96 hours
|
3
|
Resverlogix Corp.
|
Aug 22, 2017 06:28PM
|
|
Re: Time
|
3
|
Resverlogix Corp.
|
Aug 22, 2017 06:20PM
|
|
Re: Courtesy
|
4
|
Resverlogix Corp.
|
Aug 18, 2017 10:36PM
|
|
Re: My Prediction for the next two weeks in order of what we would like to see.
|
3
|
Resverlogix Corp.
|
Aug 18, 2017 12:27AM
|
|
Re: A clinical future for RVX-2135 or just a pre-clinical tool
|
5
|
Zenith Epigenetics
|
Aug 17, 2017 02:37PM
|
|
Re: Three Nature Medicine Articles on BET inhibitors and Prostate Cancer
|
3
|
Zenith Epigenetics
|
Aug 17, 2017 02:43AM
|
|
Re: A clinical future for RVX-2135 or just a pre-clinical tool
|
6
|
Zenith Epigenetics
|
Aug 17, 2017 02:41AM
|
|
Re: Resverlogix (RVX) Reports Fiscal Year 2017 Results
|
8
|
Resverlogix Corp.
|
Aug 15, 2017 03:58PM
|
|
Re: Resverlogix (RVX) Reports Fiscal Year 2017 Results
|
3
|
Resverlogix Corp.
|
Aug 15, 2017 10:11AM
|
|
Re: A clinical future for RVX-2135 or just a pre-clinical tool
|
7
|
Zenith Epigenetics
|
Aug 13, 2017 06:57PM
|
|
Re: A clinical future for RVX-2135 or just a pre-clinical tool
|
5
|
Zenith Epigenetics
|
Aug 12, 2017 05:53PM
|
|
Re: I think I actually prefer silence....
|
3
|
Resverlogix Corp.
|
Aug 12, 2017 01:47AM
|
|
Re: Q3 Events updated
|
4
|
Resverlogix Corp.
|
Aug 10, 2017 11:47PM
|
